Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2008 1
2018 2
2019 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy.
Frankish J, Mukherjee D, Romano E, Billian-Frey K, Schröder M, Heinonen K, Merz C, Redondo Müller M, Gieffers C, Hill O, Thiemann M, Honeychurch J, Illidge T, Sykora J. Frankish J, et al. Among authors: redondo muller m. Front Immunol. 2023 May 26;14:1160116. doi: 10.3389/fimmu.2023.1160116. eCollection 2023. Front Immunol. 2023. PMID: 37304285 Free PMC article.
Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.
Bartz R, Fukuchi K, Ohtsuka T, Lange T, Gruner K, Watanabe I, Hayashi S, Oda Y, Kawaida R, Komori H, Kashimoto Y, Wirtz P, Mayer JA, Redondo-Müller M, Saito S, Takahashi M, Hanzawa H, Imai E, Martinez A, Hanai M, Häussinger D, Chapman RW, Agatsuma T, Bange J, Abraham R. Bartz R, et al. Among authors: redondo muller m. Mol Cancer Ther. 2019 Oct;18(10):1832-1843. doi: 10.1158/1535-7163.MCT-18-0048. Epub 2019 Jul 26. Mol Cancer Ther. 2019. PMID: 31350344